ATE118247T1 - Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält. - Google Patents
Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält.Info
- Publication number
- ATE118247T1 ATE118247T1 AT89309440T AT89309440T ATE118247T1 AT E118247 T1 ATE118247 T1 AT E118247T1 AT 89309440 T AT89309440 T AT 89309440T AT 89309440 T AT89309440 T AT 89309440T AT E118247 T1 ATE118247 T1 AT E118247T1
- Authority
- AT
- Austria
- Prior art keywords
- gene
- replication competent
- heterologue
- provirus
- vector containing
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 230000010076 replication Effects 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001524 infective effect Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- AIDS & HIV (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24991888A | 1988-09-27 | 1988-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE118247T1 true ATE118247T1 (de) | 1995-02-15 |
Family
ID=22945570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89309440T ATE118247T1 (de) | 1988-09-27 | 1989-09-18 | Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6033902A (de) |
| EP (1) | EP0361749B1 (de) |
| JP (1) | JPH02211882A (de) |
| AT (1) | ATE118247T1 (de) |
| CA (1) | CA1336075C (de) |
| DE (1) | DE68921034D1 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| DE69033975T2 (de) * | 1989-01-23 | 2002-10-02 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Rekombinanttherapien für Infektionen und hyperproliferative Störungen |
| AU648261B2 (en) * | 1989-08-18 | 1994-04-21 | Novartis Vaccines And Diagnostics, Inc. | Recombinant retroviruses delivering vector constructs to target cells |
| US5334498A (en) * | 1992-08-18 | 1994-08-02 | Arch Development Corporation | Herpes simplex virus 1 UL13 gene product: methods and compositions |
| US6242187B1 (en) * | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| EP0852626B1 (de) * | 1996-01-29 | 2002-04-03 | Virologic, Inc. | Verfahren und zusammensetzungen zur bestimmung der empfindlichkeit und resistenz gegen antivirale wirkstoffe und screening für antivirale wirkstoffe |
| US20020034732A1 (en) * | 1997-07-30 | 2002-03-21 | Daniel J. Capon | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US20030028011A1 (en) * | 1997-07-30 | 2003-02-06 | Parkin Neil T. | Compositions and methods for determining susceptibility of hepatitis C virus to anti-viral drugs |
| US7037644B1 (en) | 1998-05-26 | 2006-05-02 | Virologic, Inc. | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| EP2386646B1 (de) * | 1998-10-01 | 2016-12-21 | University Of Southern California | Genlieferungssystem und Verwendungsverfahren |
| US6899871B2 (en) * | 1998-10-01 | 2005-05-31 | University Of Southern California | Gene delivery system and methods of use |
| US7138231B2 (en) * | 2000-09-15 | 2006-11-21 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US7186506B1 (en) | 2000-06-12 | 2007-03-06 | Monogram Biosciences, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US6869759B1 (en) | 1999-06-22 | 2005-03-22 | Virologic, Inc. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| US20030108857A1 (en) * | 2001-06-04 | 2003-06-12 | Parkin Neil T. | Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS |
| AU7268000A (en) * | 1999-07-21 | 2001-02-13 | Martin Heinkelein | Method for quantization of the antiviral effect of antiviral active principles |
| AU7535701A (en) * | 2000-06-09 | 2001-12-24 | Bristol Myers Squibb Co | Hiv-1 reporter viruses and their use in assaying anti-viral compounds |
| US6653081B2 (en) * | 2000-06-12 | 2003-11-25 | Virologic, Inc. | Methods for monitoring antiretroviral therapy and guiding therapeutic decision in the treatment of HIV/AIDS |
| EP1283272B1 (de) * | 2001-08-08 | 2013-11-13 | Janssen R&D Ireland | Verfahren und Mittel zur Bewertung einer gegen das HIV Hüllprotein (env) gerichteten Inhibitortherapie |
| US7384734B2 (en) * | 2002-02-15 | 2008-06-10 | Monogram Biosciences, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| CN1678757A (zh) * | 2002-07-01 | 2005-10-05 | 瓦罗洛吉克公司 | 测定致病病毒复制能力的组合物和方法 |
| AU2003256460A1 (en) * | 2002-07-01 | 2004-01-19 | Virologic, Inc. | Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors |
| CN1688719A (zh) * | 2002-07-01 | 2005-10-26 | 瓦罗洛吉克公司 | 确定致病性病毒对蛋白酶抑制剂易感性的组合物和方法 |
| US7736848B2 (en) * | 2002-09-30 | 2010-06-15 | Fox Chase Cancer Center | Cellular targets for treatment of retroviral infection |
| WO2005076893A2 (en) * | 2004-02-06 | 2005-08-25 | Virologic, Inc. | Compositions and methods for determining the replication capacity of a pathogenic virus |
| WO2005094288A2 (en) * | 2004-03-29 | 2005-10-13 | Virologic, Inc. | Compositions and methods for determining epistatic relationships between hiv mutations that affect replication capacity |
| US20060094020A1 (en) * | 2004-10-29 | 2006-05-04 | Parkin Neil T | Methods and compositions for determining resistance or susceptibility of HIV-1 to stavudine |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| HUE037408T2 (hu) | 2011-06-10 | 2018-08-28 | Univ Oregon Health & Science | CMV glikoproteinek és rekombináns vektorok |
| CA2789539A1 (en) | 2011-09-12 | 2013-03-12 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| ES2631608T3 (es) | 2012-06-27 | 2017-09-01 | International Aids Vaccine Initiative | Variante de la glicoproteína Env del VIH-1 |
| ES2786051T3 (es) | 2012-10-25 | 2020-10-08 | Tocagen Inc | Vector retroviral con casete de mini-promotor |
| EP2848937A1 (de) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Verfahren zur Identifizierung neuartiger HIV-1-Immunogene |
| US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
| US10322172B2 (en) * | 2014-02-10 | 2019-06-18 | Nutech Ventures | Live, attenuated vaccines and methods of making and using |
| EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
| US9931394B2 (en) | 2015-03-23 | 2018-04-03 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3588134T2 (de) * | 1984-12-24 | 1997-03-20 | Genentech Inc | Fusionen von AIDS-verwandten Polypeptiden |
| GB8525615D0 (en) * | 1985-10-17 | 1985-11-20 | Hoffmann La Roche | Polypeptides |
| WO1988003562A1 (en) * | 1986-11-01 | 1988-05-19 | Oxford Gene Systems Limited | Particulate hybrid hiv antigens |
| FR2607518B1 (fr) * | 1986-12-01 | 1989-10-20 | Transgene Sa | Vecteur viral et adn recombinant codant pour la proteine p25 du virus agent causal du s.i.d.a., culture cellulaire infectee, proteine obtenue, vaccin et anticorps obtenus |
| ATE126534T1 (de) * | 1987-05-29 | 1995-09-15 | Dana Farber Cancer Inst Inc | Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung. |
-
1989
- 1989-09-18 AT AT89309440T patent/ATE118247T1/de not_active IP Right Cessation
- 1989-09-18 DE DE68921034T patent/DE68921034D1/de not_active Expired - Lifetime
- 1989-09-18 EP EP89309440A patent/EP0361749B1/de not_active Expired - Lifetime
- 1989-09-27 CA CA000613694A patent/CA1336075C/en not_active Expired - Fee Related
- 1989-09-27 JP JP1251693A patent/JPH02211882A/ja active Pending
-
1992
- 1992-12-08 US US07/987,572 patent/US6033902A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6033902A (en) | 2000-03-07 |
| DE68921034D1 (de) | 1995-03-23 |
| JPH02211882A (ja) | 1990-08-23 |
| CA1336075C (en) | 1995-06-27 |
| EP0361749A1 (de) | 1990-04-04 |
| EP0361749B1 (de) | 1995-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE118247T1 (de) | Vektor, der ein replikationskompetentes hiv-i- provirus und ein heterologes gen enthält. | |
| DE3760912D1 (en) | Retrovirus of the type hiv-2 capable of inducing aids, and the antigenic and nucleic acid components thereof | |
| DK5189A (da) | Antihypertensivt farmaceutisk praeparat, deri indgaaende imidazolderivater og disses fremstilling | |
| ATE241014T2 (de) | Hiv-2 varianten | |
| DK172089D0 (da) | 1,3-dioxolanderivater samt fremgangsmaade til fremstilling deraf | |
| BG102041A (en) | Oxidized heterocycles containing sulphonamide aspartylprotease inhibitors | |
| DK464578A (da) | Fremgangsmaade til fremstilling af 3-substituerede og 6-substituerede 7-oxo-1-azabicyclo (3,2,0) hept-2-en-2-carxylsyrer eller amiier deraf | |
| DK53990D0 (da) | Fremgangsmaade til at frembringe en oxiderende flamme, en braender og anvendelsen af en braender | |
| ATE91728T1 (de) | Legierung auf nickel-basis. | |
| ATE172992T1 (de) | Übergangsmetallverbindung | |
| DK0400522T3 (da) | Fremgangsmåde til fremstilling af mikroniserede bionedbrydelige partikler | |
| JPS51111919A (en) | A joint block for underdrains | |
| GB2046508B (en) | Ring laser gyroscope anode | |
| NO880935D0 (no) | Fremgangmsaate for paavisning av hiv eller annet virus med lignende klinisk virkning. | |
| IL85913A0 (en) | Combination beam combiner and beam emitter for ring laser gyroscope | |
| DK153790C (da) | Fremgangsmaade til fremstilling af 2,3-dihydro-2,2-dimethyl-7-hydroxybenzofuran og 3-isobutenyl-1,2-dihydroxybenzen til anvendelse som udgangsmateriale ved fremgangsmaaden | |
| DK398486D0 (da) | Apparat til amplitudemodulation af udgangssignalet fra en laserdiode eller l.e.d. | |
| GB2227878B (en) | Ring laser gyroscope | |
| DE59002977D1 (de) | Ringlaserkreisel. | |
| FI881123L (fi) | Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar. | |
| GR1000146B (el) | Μεθοδος παρασκευης νεων 5-μεθοξυ-αλκυλαμωνιο-τετραυδροφουρανιων και -τετραυδροθειοφαινιων | |
| DK0490383T3 (da) | Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf | |
| EP0419279A3 (en) | Ring laser gyroscopes | |
| AR230999A1 (es) | Medio de cultivo,para el desarrollo de virus de leucosis bovina,de para influencia 3 o de herpes suis en cultivo en suspencion,procedimiento para el desarrollo en dicho medio de cultivo y medio de diagnostico en base a los virus desarrollados | |
| NO891691D0 (no) | Rekombinant gag-forloeper for hiv. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |